Based on discussions between 80 cross-industry Field Medical colleagues from small to large biopharmaceutical and medtech companies, this article highlights key actions for Medical Affairs teams to consider for implementation in their own organizations.
This article outlines the aspects of Medical Affairs strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases, providing a roadmap for MA teams and organizations undertaking this planning.
In Q&A format, this article summarizes key learnings from a MAPS 2022 Global Annual Meeting panel presented by the Medical Strategy FAWG.
This white paper by the MAPS Executive Consortium synthesizes the views of senior global Medical Affairs leaders to provide a unified vision for the future of Medical Affairs in society, industry, teams and as individuals.
Digital tools power the ability of Medical Affairs teams to generate, analyze and disseminate data to external stakeholders across the product lifecycle, while bringing essential learnings from these stakeholders back to the organization in the form of insights.
This paper explores the Medical Affairs-based medical insights function and and identifies basic operational elements required to establish medical insights as a core strategic MA function.
What is Medical Affairs and what does it do in the biopharmaceutical and MedTech industries? Who works in Medical Affairs and what skills do you need to succeed? Find out in this essential guide to understanding, joining and thriving in Medical Affairs.
Medical technologies require equipping health care providers with the theoretical knowledge of best and safest use and also ensuring users’ practical competence. This article by the MAPS MedTech and External Education FAWGs overviews these best practices.
In this white paper, MedComms, Field Medical and Insights Focus Area Working Groups (FAWGs) demonstrate the value of and elucidate best practices for an insights-driven collaborative approach to creating an iMC S/P.
This white paper provides Medical Affairs professionals with the background and history of Real-World Evidence, and its applications in the biopharma industry to benefit patients.